Improved DNA sequencing platform offers improved productivity of high-throughput, large-scale genome sequencing
Amersham Biosciences introduces the Megabace 4500 DNA sequence analyser, an improved version of its 384 capillary Megabace 4000. The new Megabace 4500 improves the average sequencing read length by approximately 150-200 base pairs.
By enabling users to achieve read lengths of greater than 900 base pairs in a single run, the new DNA sequencing analyser is said to significantly improve the productivity of high-throughput, large scale genome sequencing. "The Megabace platform has set the standard for high-throughput DNA sequencing and played a key role in the efforts to sequence the human genome," said Michael Pettigrew, vice president of drug discovery sales at Amersham Biosciences.
"The ability of the Megabace 4500 to accelerate the sequencing process, improve accuracy, and reduce the cost per base sequenced will ensure that Megabace continues to play a critical role in the ongoing sequencing of the genomes of many different organisms and micro-organisms".
Amersham Biosciences' Megabace was the first 384-capillary gel electrophoresis sequencing system on the market, revolutionising high-throughput DNA sequence analysis.
The Megabace 4500 provides longer read lengths, longer-lasting arrays, and more efficient excitation of low signal samples due to a number of technological advances.
It offers an enhanced sieving matrix, a new, 70cm capillary length, and elevated (up to 60C) operating temperatures.
Ease of operation is an additional advantage.
